Robert D. Tessarolo was appointed President and Chief Executive Officer of Cipher Pharmaceuticals, effective April 17, 2017 and was subsequently elected to the Board of Directors in May 2017.
Mr. Tessarolo has 22 years of experience in the pharmaceutical industry spanning business strategy, general management and commercial operations roles across multiple countries and therapeutic areas. He has demonstrated expertise in leading pharmaceutical organizations through start-up opportunities, turnaround challenges and delivering rapid growth, expansion and value creation.
Mr. Tessarolo most recently held the position of Vice President & General Manager with Celgene Corporation, where he was responsible for leading their U.S. Inflammation & Immunology business. He contributed to the substantial expansion of the U.S. business in 2016, which was led by the rapid growth of Otezla for plaque psoriasis and psoriatic arthritis.
Prior to Celgene, Mr. Tessarolo led the launch of Actavis, plc’s Canadian Specialty Pharmaceutical Division and served as President and General Manager. Under his leadership, Mr. Tessarolo rapidly expanded the Canadian business, leading his team through several new product launches and the successful integration of multiple company acquisitions, including Warner Chilcott, Forest Labs and Allergan. Earlier he started his career as sales representative with Biovail Pharmaceuticals and held positions of increasing responsibility culminating in his appointment to the position of Vice President and General Manager.
Mr. Tessarolo had direct oversight and accountability for country strategy, operations, business development and financial responsibilities for each of the Canadian entities he has led.
Mr. Tessarolo serves on the Board of Directors of Bradmer Pharmaceuticals. He is a graduate of Carleton University with a B.A. in Economics and has attended the Advanced Management Program for General Management at Ross School of Business at the University of Michigan.